Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Other financing activities (2019 - 2025)

Haemonetics has reported Other financing activities over the past 15 years, most recently at -$89000.0 for Q4 2025.

  • Quarterly results put Other financing activities at -$89000.0 for Q4 2025, up 99.62% from a year ago — trailing twelve months through Dec 2025 was -$116000.0 (down 122.35% YoY), and the annual figure for FY2025 was -$249000.0, down 241.1%.
  • Other financing activities for Q4 2025 was -$89000.0 at Haemonetics, down from -$27000.0 in the prior quarter.
  • Over the last five years, Other financing activities for HAE hit a ceiling of $23.2 million in Q3 2024 and a floor of -$23.4 million in Q4 2024.
  • Median Other financing activities over the past 5 years was -$13000.0 (2022), compared with a mean of -$27882.4.
  • Biggest five-year swings in Other financing activities: skyrocketed 12666.67% in 2022 and later crashed 43353.7% in 2024.
  • Haemonetics' Other financing activities stood at -$9000.0 in 2021, then tumbled by 12677.78% to -$1.2 million in 2022, then soared by 104.7% to $54000.0 in 2023, then crashed by 43353.7% to -$23.4 million in 2024, then soared by 99.62% to -$89000.0 in 2025.
  • The last three reported values for Other financing activities were -$89000.0 (Q4 2025), -$27000.0 (Q1 2025), and -$23.4 million (Q4 2024) per Business Quant data.